Notícias

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SYK launches TPX HD, a small bone power tool built for complex revisions, MIS and oral maxillofacial cases with higher torque and speed.

PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.

AMN Healthcare is riding MSP momentum, labor disruption demand and AI platforms, yet faces pricing pressure and post-disruption volatility.

NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.

Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.

PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.

Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HQY tops Q1 FY27 EPS and revenue estimates as HSA accounts and assets climb, and guidance for FY27 revenues and adjusted EPS rises.

NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.

SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.

BTSG leans on surging Specialty & Infusion and integrated home health branches, but IRA and generic shifts may pressure 2026 margins.

NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.

West Pharmaceutical Services has considerably outperformed the broader market over the past 52 weeks, and Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.

Recent performance snapshot West Pharmaceutical Services (WST) has drawn investor attention after a period of solid share performance, with the stock roughly flat over the past day but higher over the past week, month and past 3 months. At a recent close of US$316.42, West Pharmaceutical Services sits on a market value of about US$22.35b, alongside reported annual revenue of US$3.22b and net income of US$542.7m from its injectable drug packaging and delivery business. See our latest analysis...

GEHC teams with UW Medicine Radiology to advance CT and molecular imaging, aiming to automate workflows and speed next-gen imaging to clinics.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.

BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.

INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.

NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.

OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.

WST's HVP business and GLP-1 demand are driving growth, but can Annex 1 tailwinds and margin gains offset inflation and SmartDose risks?

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

By Sahil Pandey May 20 (Reuters) - West Pharmaceutical Services said on Wednesday it has restored operations across its sites after a cybersecurity attack earlier this month and expects the incident

PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.

ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.

DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.

CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.

Natera wins FDA approval for Signatera CDx in bladder cancer, marking the first blood-based MRD companion diagnostic milestone.

MD gains from stronger cash collections, payer mix and acquisitions, while telehealth expansion and buybacks support growth.